Parabilis Medicines announced updated Phase 1/2 trial data for zolucatetide, showing a 72.2% objective response rate and 100% disease control in patients with desmoid tumors at doses ≥450 mg. The drug demonstrated strong efficacy and a favorable safety profile, with no disease progression or treatment discontinuations due to adverse events. The FDA has aligned with the proposed dose and trial design, allowing Parabilis to initiate the Phase 3 PEDESTAL trial in early 2027, with results expected in 2029. This advancement offers hope for a new treatment targeting a previously undruggable pathway in desmoid tumors, a rare and challenging disease.
Parabilis Medicines' updated Phase 1/2 data for zolucatetide offers context for readers tracking health sector developments. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 24, 2026 18:11 WIB: out of 150 priced US health stocks, 44 rose and 105 fell. Notable movers include TNGX at USD 23.34 with a -16.43% change and 87% sell orders, WGS at USD 56.15 with a -16.37% change and balanced buy/sell activity, and CTXR at USD 0.40 with an +8.79% change and 98% buy orders. Typical hold times range from 1 to 20 days.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
McDonald's announced the return of its McRib sandwich on October 27, reigniting a quirky market superstition linking the McRib's comeback to bullish bitcoin price movements. Historically, bitcoin posted gains after six McRib returns from 2019 to 2024...
Newmont Corporation's Q3 earnings report failed to boost investor confidence as it highlighted ongoing cost pressures expected in 2027, alongside falling gold prices and record-low trading volumes. These factors suggest a period of increased volatili...
